The US FDA released a draft guidance on 21st October 2024 outlining the recommendations for "Drug Interaction Information in Human Prescription Drug and Biological Product Labeling". The purpose of this guidance is to help applicants determine where and how to place drug interaction information (DI) information in human prescription drugs and biological products as outlined in the regulations for labeling human prescription drugs and biological products.
Drug interactions can have significant implications on the safety and efficacy of therapies. As a result, the FDA aims to standardize how drug interaction information is communicated in product labeling.
As part of this guidance, recommendations are provided to help ensure that DI information is consistently placed in the proper sections and subsections within labeling to ensure that it is easy to understand and accessible for health care practitioners (HCPs) and includes content that ensures the drug is used safely and effectively.
The Drug Interactions section of the labeling provides detailed information about how the product interacts with other drugs or substances, affecting its safety or efficacy. The FDA emphasizes that this section should present drug interactions in a concise, clinically relevant format. This section should allow healthcare providers to quickly understand and manage potential risks when prescribing medications.
The FDA recommends that drug interactions that could lead to serious adverse events or therapeutic failure should be prioritized in this section. This includes drug interactions that could require:
Dose adjustments
Therapeutic monitoring
Avoiding certain drug combinations
Examples of clinically significant drug interactions include interactions between anticoagulants and other drugs that increase bleeding risk, or interactions between antibiotics and oral contraceptives that may reduce contraceptive efficacy. Equally important is the need to communicate when no clinically significant interaction is expected between drugs. This helps healthcare providers avoid unnecessary monitoring or adjustments.
Drug interaction information may also appear in other sections of the full prescribing information, particularly if it has implications for safety or dosing. These sections include:
Warnings and Precautions: Significant drug interactions that can result in severe adverse effects.
Dosage and Administration: Instructions on adjusting doses when drugs are co-administered.
Contraindications: Drug combinations that should be avoided entirely due to potential harm.
The FDA encourages aligning the information across these sections to avoid redundancy while ensuring clarity.
By providing clear, actionable guidance in the Drug Interactions section and ensuring consistency throughout the labeling, this guidance helps healthcare providers make informed decisions, improving patient safety and treatment efficacy. For more information, you can access the full FDA guidance document via the following links:
Comments